China Traditional Chinese Medicine (570.HK) - Short-Term Performance Pressure Is Hard to Avoid
For poor performance of concentrated TCM granule, China TCM's net profit decreased 50%-60% in 2022H1.Future VBP will further drag down profitability, which will struggle to support valuation expansion